Sign up for On-Demand Alert Get Credit

Benign and Malignant Esophageal Disease
Tuesday, June 15th from 5 - 6 p.m. EDT

Join Roswell Park Comprehensive Cancer Center physicians for a virtual forum on Benign and Malignant Esophageal Disease. They will be discussing several of the new advances available to help us better contain this dangerous disease. The live CME will be moderated by Steven Hochwald, MD, MBA, FACS, Chief of Gastrointestinal/Endocrine Surgery and Vice Chair of Department of Surgical Oncology at Roswell Park Comprehensive Cancer Center. The event will include four brief talks followed by a Q&A session for each participant.

Instruction format: LIVE Video Presentation
Cost: Complimentary
Credits: 1.0 AMA PRA Category 1 Credit™

The LIVE webinar will start to stream to this page beginning at 5:00 PM EDT. If the live webinar player is not showing above, please refresh your page and click the play button to join.

Moderated by:

Steven Hochwald, MD, MBA, FACS
Steven Hochwald, MD, MBA, FACS
Chief of Gastrointestinal/Endocrine Surgery
Vice Chair of Department of Surgical Oncology
Professor of Oncology


Moshim Kukar, MD, FACS
Moshim Kukar, MD, FACS
Associate Professor of Oncology
Department of Surgical Oncology
Robotic Management of Gastroesophageal Junction
Todd Demmy, MD, FACS
Todd Demmy, MD, FACS
Professor of Oncology, Thoracic Surgery and Oncology
POEM for Achalasia: Indications and Outcomes
Sarbajit Mukherjee, MD, MS
Sarbajit Mukherjee, MD, MS
Assistant Professor of Oncology, Department of Medicine
Member, Tumor Immunology and Immunotherapy Program
Advances in Esophageal Cancer


Activity Planners

Ashley Snowden
Director, Physician and Corporate Relations
Roswell Park Comprehensive Cancer Center
Elm & Carlton Streets
Buffalo, NY

Danielle M. Fleischmann, CPC
Physician Relations Liaison
Roswell Park Cancer Institute
Elm & Carlton Streets
Buffalo, NY

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Statement Of Need

Esophageal cancer is difficult to treat and associated with poor patient survival. Learners need to demonstrate consistent quality outcomes for esophagectomy with a mortality rate of <5%----preferably less than 3%. Learners need to be able to demonstrate a diversified surgical approach with application of clinical pathways. The need to demonstrate effective communication with their colleagues including those in interventional gastroenterology and oncology with participation in tumor boards. Documenting their survival results for the treatment of patients with esophageal cancer and be involved with the enrollment of patients with esophageal cancer into national clinical trials. Learners should understand that regionalization of care for esophageal cancer may result in the further development of high volume centers with low mortality following esophagectomy.

For high grade dysplasia of the esophagus and early esophageal cancer, participants should understand the endoscopic advances available and refer appropriate patients for endoscopic therapy.

For advanced disease, participants should understand the role of multimodality therapy and current advances in care for metastatic esophageal cancer.

For achalasia of the esophagus, participants should understand the role of per oral myotomy to treat this benign condition. Use of endoscopic per oral myotomy will obviate the need for surgery for achalasia.

Target Audience

This activity is intended for physicians and advanced practice providers in gastroenterologists, surgeons, medical oncologists, primary care physicians and their medical staff.

Learning Objectives

Upon completion, participants should be able to:

  • Identify the appropriate use of multimodality therapy for esophageal cancer and treatment of advanced esophageal cancer with novel agents to improve survival
  • Identify the appropriate patients to be treated with endoscopic therapy and results from these therapies for benign disease
  • Identify newer methods of palliating motility disorders along with their advantages and disadvantages
  • Understand the advanced endoscopic procedures available to treat high grade dysplasia and early carcinoma of the esophagus
  • Understand the GE junction and esophageal malignancies that may be amenable to endoscopic management
  • Understand the quality outcomes for esophagectomy with a mortality rate of <5%

Joint Providership Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Med-IQ and Roswell Park. Med-IQ is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Med-IQ designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Instructions To Receive Credit

To receive credit, read the introductory CME material, attend the entire virtual meeting, and complete evaluation, and attestation via web link.

Participants must complete the evaluation and attestation within 60 days of participation.


The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity.


The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, andhave stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Todd Demmy, MD, FACS
Consulting fees/advisory boards: Midton
Steven Hochwald, MD, MBA, FACS, has indicated no real or apparent conflicts.
Moshim Kukar, MD, FACS, has indicated no real or apparent conflicts.
Sarbajit Mukherjee, MD, MS, has indicated no real or apparent

The peer reviewers and activity planners have no financial relationships to disclose.

Statement Of Evidence-Based Content

Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information

For CME questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email

Created by

Roswell Park Comprehensive Cancer Center